Ayala Pharmaceuticals Inc (AYLA) falls -2.5660% for June 18

Equities Staff  |

Ayala Pharmaceuticals Inc (NASDAQ: AYLA) shares fell -2.5660% to end trading Friday at $11.01 per share - a net change of $-0.29. Shares traded between $11.84 and $11.01 throughout the day.

About Ayala Pharmaceuticals Inc

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE).

Visit Ayala Pharmaceuticals Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Ayala Pharmaceuticals Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Ayala Pharmaceuticals Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Beyond Meat To Launch Meatless Chicken Tenders at Grocery Stores in October
President Biden Hosting Leaders From India, Japan, Australia Friday in First 'Quad' Summit
Some Chinese Banks Stop Offering New Credit to Property Developers Amid Evergrande Scare
Iowa Senator Chuck Grassley Seeks Eighth Term of Office
House Select Committee Subpoenas Four Trump Allies in US Capitol Riot Probe
CDC Endorses COVID-19 Vaccine Booster Shots for Millions of Older and Vulnerable Individuals
Semiconductor Shortage To Cost Global Auto Industry $210 Billion in Revenue in 2021
US Olympic Athletes Must Have COVID-19 Vaccination for Beijing Winter Games



Market Movers

Sponsored Financial Content